Skip to content

Tranexamic acid used in joint replacement operation in perioperative period

Tranexamic acid used in joint replacement operation in perioperative period

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15005884
Enrollment
Unknown
Registered
2015-01-25
Start date
2015-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tranexamic acid used in joint replacement operation in perioperative period

Interventions

The local use of tranexamic acid group :The local use of tranexamic acid
Tranexamic acid group with vein:Tranexamic acid with vein

Sponsors

People's Hospital of Karamay City, Xinjiang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patient younger than 80 years old; No cognitive impairment, communication difficulties or mental and neurological diseases; No alcohol or drug dependence syndrome; no morphine or local anesthetic allergy history; for the non steroidal anti-inflammatory drug allergy history; No liver and kidney dysfunction and coagulation dysfunction; No history of peptic ulcer disease and hemorrhagic disease history; Preoperative Hgb, PLT, blood coagulation function were normal; Preoperative double lower limb venous ultrasound showed no abnormalities; The patients were informed consent, and approval from the hospital ethics committee.

Exclusion criteria

Exclusion criteria: 1) had had a previous DVT; 2) use TXA taboo: including the tendency of thrombosis in patients with atrial fibrillation, stent implantation, patients with pacemaker implantation patients; 3) blood coagulation function disorder; combined with severe coagulopathy, active gastric ulcer or are receiving anticoagulant treatment in patients with; 4) TXA allergy; 5) serious heart, lung, liver, renal insufficiency patients; Body mass index; 6) body mass index (BMI) is greater than 35; 7) bilateral knee OA or undergoing knee artificial revision arthroplasty patients.

Design outcomes

Primary

MeasureTime frame
Blood loss;Hb;

Countries

China

Contacts

Public ContactYue Yong
yueyong54321@qq.com+86 18999505353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026